Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neogenomics Inc (NQ: NEO )

17.90 -0.27 (-1.49%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 943,947
Open 18.07
Bid (Size) 16.37 (6)
Ask (Size) 18.71 (1)
Prev. Close 18.17
Today's Range 17.86 - 18.48
52wk Range 12.77 - 21.22
Shares Outstanding 122,816,314
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NeoGenomics’ Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma
From NeoGenomics, Inc.
Via Business Wire
Evaluating NeoGenomics: Insights From 4 Financial Analysts
Via Benzinga

Performance

YTD
+12.23%
+12.23%
1 Month
+9.61%
+9.61%
3 Month
+10.49%
+10.49%
6 Month
+33.38%
+33.38%
1 Year
-5.89%
-5.89%

More News

Read More
NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting
From NeoGenomics, Inc.
Via Business Wire
Expert Ratings For NeoGenomics
Via Benzinga
NEO Stock Earnings: NeoGenomics Beats Revenue for Q2 2024
Via InvestorPlace
NeoGenomics Earnings Analysis: Q1 Recap
Via Benzinga
Where NeoGenomics Stands With Analysts
Via Benzinga
NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
From NeoGenomics, Inc.
Via Business Wire
Felicia Williams Joins NeoGenomics Board of Directors
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Reports Third Quarter 2024 Results
From NeoGenomics, Inc.
Via Business Wire
Earnings Scheduled For November 14, 2024
Via Benzinga
NeoGenomics Receives New York State Approval for Neo Comprehensive™ Solid Tumor Test
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Present New Data at ESMO 2024, Highlighting the Value of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From NeoGenomics, Inc.
Via Business Wire
Shake Shack And Lumen Tech Are Among Top 7 Mid Cap Stocks With Max Gains Last Week (July 28-August 3): Are The Others In Your Portfolio?
Via Benzinga
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
PayPal Posts Upbeat Earnings, Joins Sprouts Farmers Market, Stanley Black & Decker, Phillips 66 And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
NeoGenomics Reports Second Quarter 2024 Results
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Report Second Quarter 2024 Financial Results on July 29, 2024
From NeoGenomics, Inc.
Via Business Wire
Fort Myers’ Mayor to Proclaim June as NeoGenomics’ Commitment to Cancer Month
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management
From NeoGenomics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.